Sign in

Keith Hinton

Director and Senior Analyst specializing in MedTech equity research at Freedom Capital Markets

Keith Hinton is a Director and Senior Analyst specializing in MedTech equity research at Freedom Capital Markets, where he covers companies such as Veracyte and focuses on diagnostics and research within the healthcare sector. He recently initiated coverage on Veracyte with a Buy rating and a $45 price target, projecting a 22.5% upside, though current metrics show an average return near 0% and a success rate that reflects new coverage activity. Hinton joined Freedom Capital Markets as part of an expansion in senior research talent and previously held a Global Managing Director role, bringing significant experience in international research leadership. He maintains senior analyst credentials in U.S. financial markets, and his responsibilities include providing in-depth research to institutional investors.

Keith Hinton's questions to GeneDx Holdings (WGS) leadership

Question · Q3 2025

Keith Hinton asked about the XGen volumes, noting they seemed to slightly exceed internal expectations based on the H2 2025 volume split discussed in the Q2 call. He inquired where GeneDx outperformed internal expectations and why the full-year guide remained unchanged despite the beat. Hinton also asked about the general pediatrician launch, specifically regarding the back-end build-up (e.g., additional billing/revenue cycle staff, DTC spend) and any concerns about potential bottlenecks in genetic counseling for patients with variants.

Answer

Kevin Feeley, CFO, stated that the outperformance in XGen volumes was primarily driven by the outpatient side of the business, particularly from farming the pediatric neurologist call point, and noted strong momentum throughout Q3. He explained that the full-year guide was maintained to reflect a balanced view. Regarding the general pediatrician launch, Feeley confirmed that investments in back-end support, including genetic counseling resources and other support for non-experts, are core to the experience design changes. He reiterated that these investments are covered by ample gross margin, ensuring the business remains profitable on an adjusted basis.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts